Curcumin, a traditional spice component, can hold the promise against COVID-19?


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 Nov 2020
Historique:
received: 10 07 2020
revised: 17 08 2020
accepted: 10 09 2020
pubmed: 16 9 2020
medline: 27 10 2020
entrez: 15 9 2020
Statut: ppublish

Résumé

The severity of the recent pandemic and the absence of any specific medication impelled the identification of existing drugs with potential in the treatment of Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Curcumin, known for its pharmacological abilities especially as an anti-inflammatory agent, can be hypothesized as a potential candidate in the therapeutic regimen. COVID-19 has an assorted range of pathophysiological consequences, including pulmonary damage, elevated inflammatory response, coagulopathy, and multi-organ damage. This review summarizes the several evidences for the pharmacological benefits of curcumin in COVID-19-associated clinical manifestations. Curcumin can be appraised to hinder cellular entry, replication of SARS-CoV-2, and to prevent and repair COVID-19-associated damage of pneumocytes, renal cells, cardiomyocytes, hematopoietic stem cells, etc. The modulation and protective effect of curcumin on cytokine storm-related disorders are also discussed. Collectively, this review provides grounds for its clinical evaluation in the therapeutic management of SARS-CoV-2 infection.

Identifiants

pubmed: 32931783
pii: S0014-2999(20)30643-9
doi: 10.1016/j.ejphar.2020.173551
pmc: PMC7832734
pii:
doi:

Substances chimiques

Curcumin IT942ZTH98

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

173551

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

J Tradit Complement Med. 2014 Jan;4(1):24-35
pubmed: 24872930
Phytother Res. 2020 Nov;34(11):2911-2920
pubmed: 32430996
Curr Pharmacol Rep. 2020;6(3):56-70
pubmed: 32395418
J Int Med Res. 2020 Apr;48(4):300060520910665
pubmed: 32237999
Expert Opin Drug Metab Toxicol. 2019 Sep;15(9):705-733
pubmed: 31361978
In Vivo. 2015 Jan-Feb;29(1):1-4
pubmed: 25600522
Drug Des Devel Ther. 2015 Nov 11;9:6043-54
pubmed: 26648693
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
Int J Mol Sci. 2020 Apr 24;21(8):
pubmed: 32344526
Sci Rep. 2019 Oct 30;9(1):15585
pubmed: 31666589
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Phys Chem Lett. 2020 Jun 4;11(11):4413-4420
pubmed: 32406687
Cell Stress Chaperones. 2020 Sep;25(5):707-710
pubmed: 32500379
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
Respir Physiol Neurobiol. 2020 Mar;274:103336
pubmed: 31778793
Med Hypotheses. 2020 Oct;143:109851
pubmed: 32534175
Int J Mol Sci. 2020 Mar 31;21(7):
pubmed: 32244288
Int J Cancer. 2011 Jan 1;128(1):242-5
pubmed: 20198612
Exp Lung Res. 2009 Dec;35(10):883-95
pubmed: 19995280
J Biomol Struct Dyn. 2021 Jun;39(9):3092-3098
pubmed: 32329419
Lancet Respir Med. 2020 Aug;8(8):807-815
pubmed: 32422178
J Med Chem. 2007 Aug 23;50(17):4087-95
pubmed: 17663539
Int J Cancer. 2010 Apr 1;126(7):1771-5
pubmed: 19830693
Nutrients. 2020 Apr 24;12(4):
pubmed: 32344708
Cell Metab. 2009 May;9(5):403-5
pubmed: 19416709
J Neuroinflammation. 2018 Jan 06;15(1):6
pubmed: 29306322
Toxicol Appl Pharmacol. 2011 May 1;252(3):298-306
pubmed: 21397623
Sci Rep. 2019 Jan 24;9(1):491
pubmed: 30679571
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Front Cell Dev Biol. 2020 Jun 12;8:479
pubmed: 32596244
Int Immunopharmacol. 2018 Aug;61:231-240
pubmed: 29894862
Molecules. 2019 Aug 13;24(16):
pubmed: 31412624
Br J Pharmacol. 2020 Nov;177(21):4813-4824
pubmed: 32329520
Front Microbiol. 2019 May 03;10:912
pubmed: 31130924
Int J Mol Sci. 2019 Oct 02;20(19):
pubmed: 31581661
Pharmacol Res. 2020 Sep;159:104921
pubmed: 32464325
Virus Res. 2020 Jul 15;284:197989
pubmed: 32360300
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
PLoS One. 2011;6(8):e23756
pubmed: 21858220
J Transl Med. 2014 Sep 21;12:266
pubmed: 25241044
Int Immunopharmacol. 2018 Jan;54:177-187
pubmed: 29153953
Molecules. 2020 Feb 07;25(3):
pubmed: 32046055
Front Oncol. 2020 Feb 07;10:109
pubmed: 32117758
Postgrad Med. 2020 Sep;132(7):604-613
pubmed: 32496926
Cell Death Differ. 2020 Nov;27(11):3196-3207
pubmed: 32514047
PLoS One. 2013;8(2):e57285
pubmed: 23437361
Influenza Other Respir Viruses. 2017 Sep;11(5):457-463
pubmed: 28646616
ACS Appl Nano Mater. 2020 May 22;3(5):4913
pubmed: 35286056
Biochim Biophys Acta. 2013 Aug;1833(8):1924-35
pubmed: 23583304
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Sci Rep. 2016 May 05;6:25579
pubmed: 27146402
Int J Biochem Cell Biol. 2020 Jun;123:105752
pubmed: 32325281
FASEB J. 2019 Dec;33(12):13294-13309
pubmed: 31530014
Virusdisease. 2020 Jun;31(2):179-193
pubmed: 32656311
Toxicol Appl Pharmacol. 2012 Aug 15;263(1):111-21
pubmed: 22714040
Life Sci. 2020 Jun 15;251:117627
pubmed: 32251634
Curr Drug Targets. 2017;18(11):1301-1313
pubmed: 27469342
Pharmacol Res. 2020 Jul;157:104859
pubmed: 32360480
Stem Cell Rev Rep. 2020 Jun;16(3):434-440
pubmed: 32307653
Cancer Res. 2013 Jun 1;73(11):3425-40
pubmed: 23548270
Pharmacol Res. 2017 Jan;115:133-148
pubmed: 27888157
J Cell Physiol. 2018 Nov;233(11):8588-8596
pubmed: 29741772
Br J Pharmacol. 2017 Jun;174(11):1325-1348
pubmed: 27638428
J Cell Biochem. 2018 Nov;119(11):8713-8722
pubmed: 30098070
J Clin Med. 2020 Jun 07;9(6):
pubmed: 32517353
Int J Antimicrob Agents. 2020 May;55(5):105955
pubmed: 32234468
Chem Biol. 2003 Aug;10(8):695-704
pubmed: 12954328
J Cell Physiol. 2018 Jun;233(6):4497-4511
pubmed: 29052850
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
Hypertension. 2006 Apr;47(4):718-26
pubmed: 16505206
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Ther Adv Chronic Dis. 2020 Jun 24;11:2040622320922104
pubmed: 32637058
Future Virol. 2011 May;6(5):615-631
pubmed: 21765859

Auteurs

Vivek Kumar Soni (VK)

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India.

Arundhati Mehta (A)

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India.

Yashwant Kumar Ratre (YK)

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India.

Atul Kumar Tiwari (AK)

Department of Zoology, Bhanwar Singh Porte Government Science College, Pendra, Chhattisgarh, India.

Ajay Amit (A)

Department of Forensic Science, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India.

Rajat Pratap Singh (RP)

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India.

Subash Chandra Sonkar (SC)

Multidisciplinary Research Unit, Maulana Azad Medical College, University of Delhi, New Delhi, India.

Navaneet Chaturvedi (N)

Department of Molecular and Cell Biology, Henry Welcome Building, University of Leicester, Leicester, LE26AW, UK; School of Biochemical Engineering, Indian Institute of Technology-Banaras Hindu University (IIT-BHU), Varanasi, Uttar Pradesh, 221005, India.

Dhananjay Shukla (D)

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India. Electronic address: sdhannu@gmail.com.

Naveen Kumar Vishvakarma (NK)

Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India. Electronic address: naveenvishva@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH